SEARCH

SEARCH BY CITATION

References

  • 1
    Brillanti S, Garson J, Foli M, et al. A pilot study of combination therapy with ribavirin plus interferon alpha for interferon alpha resistant chronic hepatitis C. Gatsroenterology 1994; 107: 81219.
  • 2
    Reichard O, Norkrans G, Fryden A, et al. Randomised, double-blind, placebo-controlled trial of interferon alpha2b with and without ribavirin for chronic heptitis C. Lancet 1998; 351: 837.
  • 3
    McHutchison JG, Gordon SC, Schiff ER, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998; 339: 148592.
  • 4
    Pawlotsky JM, Dahari H, Neumann AU, et al. Antiviral action of ribavirin in chronic hepatitis C. Gastroenterology 2004; 126: 70314.
  • 5
    Bronowicki JP, Ouzan D, Asselah T, et al. Effect of ribavirin in genotype 1 patients with hepatitis C responding to pegylated interferon alfa-2a plus ribavirin. Gastroenterology 2006; 131: 10408.
  • 6
    Hofmann WP, Polta A, Herrmann E, et al. Mutagenic effect of ribavirin on hepatitis C nonstructural 5B quasispecies in vitro and during antiviral therapy. Gastroenterology 2007; 132: 92130.
  • 7
    Chevaliez S, Brillet R, Lazaro E, Hezode C, Pawlotsky JM. Analysis of ribavirin mutagenicity in human hepatitis C virus infection. J Virol 2007; 81: 773241.
  • 8
    Chung RT, Gale M Jr, Polyak SJ, et al. Mechanisms of action of interferon and ribavirin in chronic hepatitis C: summary of a workshop. Hepatology 2008; 47: 30620.
  • 9
    Asselah T, Bièche I, Sabbagh A, et al. Gene expression and hepatitis C virus infection. Gut 2009; 58: 84658.
  • 10
    Feld JJ, Lutchman GA, Heller T, et al. Ribavirin improves early responses to peginterferon through improved interferon signaling. Gastroenterology 2010; 139: 15462.
  • 11
    Thomas E, Feld JJ, Li Q, et al. Ribavirin potentiates interferon action by augmenting interferon-stimulated gene induction in hepatitis C virus cell culture models. Hepatology 2011; 53: 3241.
  • 12
    Pockros PJ, Nelson D, Godofsky E, et al. R1626 plus peginterferon Alfa-2a provides potent suppression of hepatitis C virus RNA and significant antiviral synergy in combination with ribavirin. Hepatology 2008; 48: 38597.
  • 13
    Hofmann WP, Chung TL, Osbahr C, et al. Impact of ribavirin on HCV replicon RNA decline during treatment with interferon-alpha and the protease inhibitors boceprevir or telaprevir. Antivir Ther 2011; 16: 695704.
  • 14
    Hézode C, Forestier N, Dusheiko G, et al. PROVE2 study team. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med 2009 Apr 30; 360: 183950.
  • 15
    McHutchison JG, Manns MP, Muir AJ, et al. Telaprevir for previously treated chronic HCV infection. N Engl J Med 2010; 362: 1292303.
  • 16
    Kwo PY, Lawitz EJ, McCone J, et al. SPRINT-1 investigators. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial. Lancet 2010; 376: 70516.
  • 17
    Gane E, Roberts S, Stedman C, et al. Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial. Lancet 2010; 376: 146775.
  • 18
    Lok A, Gardiner D, Lawitz E, et al. Quadruple therapy with BMS-790052, BMS-650032 and PEG-IFN/RBV for 24 weeks; results in 100% SVR12 in HCV genotype 1 null responders. 46th Annual Meeting of the European Association for the Study of the Liver (EASL 2011). Berlin, Germany. March 30–April 3. Abstract 418, 2011.
  • 19
    Zeuzem S, Asselah T, Angus PW, et al. Strong antiviral activity and safety of IFN – sparing treatment with the protease inhibitor BI 201335, the HCV polymerase inhibitor BI 207127 and ribavirin in patients with chronic hepatitis C. Gastroenterology 2011; 141: 204755.
  • 20
    Zeuzem S, Buggisch P, Agrawal K, et al. Dual, triple, and quadruple combination treatment with a protease inhibitor (GS -9256) and a polymerase inhibitor (GS – 9190) alone and in combination with ribavirin (RBV) or PegIFN/RBV for up to 28 days in treatment naive, genotype 1 HCV subjects. The 61th annual meeting of the American Association for the Study of Liver Diseases, October 29–November 2, Boston, MA, USA, 2010.
  • 21
    Zeuzem S, Buggisch P, Agarwal K, et al. Dual, triple, and quadruple combination treatment with a protease inhibitor (GS-9256) and a polymerase inhibitor (GS-9190) alone and in combination with ribavirin (RBV) or PegIFN/RBV for up to 28 days in treatment naïve, genotype 1 HCV subjects. 61st Annual Meeting of the American Association for the Study of Liver Diseases (AASLD 2010). Boston, MA, USA, October 29–November 2, 2010. Abstract LB-1.
  • 22
    Di Bisceglie AM, Nelson DR, Gane E, et al. Presented at: EASL. The 46th Annual International Liver Congress 2011; March 30–April 3, 2011; Berlin, Germany. Abstract 1363.
  • 23
    Lawitz E, Rodriguez-Torres M, Denning J, et al. Once daily dual-nucleotide combination of PSI-938 and PSI-7977 provides 94% HCV RNA < LOD at day 14: first purine/pyrimidine clinical combination data (the nuclear study). 46th Annual Meeting of the European Association for the Study of the Liver (EASL 2011). Berlin, Germany. March 30–April 3. Late Breaker presentation, 2011.
  • 24
    Asselah T, Marcellin P. New direct-acting antivirals’ combination for the treatment of chronic hepatitis C. Liver Int 2011; 31(Suppl 1): 6877.
  • 25
    Bodenheimer HC, Linsay KL, Davis GL, et al. Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: a multicenter trial. Hepatology 1997; 26: 4737.